Iya Khalil is a fast talker, she readily admits. But she’s not afraid to admit that her company, Gene Network Sciences (GNS), has had to pause and change its tune over the past decade in order to establish fruitful business partnerships with pharma. However, the latest version of its supercomputer-based scientific platform called REFS (Reverse Engineering, Forward Simulation) and efforts to harness complete ‘omic and clinical data are putting GNS on the right track.
Tailoring Medicine with Supercomputers
March 16, 2010